Autor: amp-admon

Atlas Molecular Pharma, closer to make the dream of having a drug for Congenital Erythropoietic Porphyria come true

The phase 1 clinical trial to test the new drug in humans was authorized and will begin soon in the United States   Congenital Erythropoietic Porphyria is an ultra-rare, severe, and highly debilitating pathology with no therapeutic options in the market nor in development until now. The disease affects less than one person per million […]